![Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial | Nature Medicine Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01694-6/MediaObjects/41591_2022_1694_Fig1_HTML.png)
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial | Nature Medicine
![Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/35/6/3415/F2.large.jpg)
Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research
![Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program | Journal for ImmunoTherapy of Cancer Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program | Journal for ImmunoTherapy of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40425-019-0579-z/MediaObjects/40425_2019_579_Fig1_HTML.png)
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program | Journal for ImmunoTherapy of Cancer
![Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial - The Lancet Oncology Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2065179678/2066267922/gr1.jpg)
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial - The Lancet Oncology
![Kaplan-Meier curve depicting the overall survival of 359 metastatic... | Download Scientific Diagram Kaplan-Meier curve depicting the overall survival of 359 metastatic... | Download Scientific Diagram](https://www.researchgate.net/publication/316168352/figure/fig3/AS:670350929039373@1536835524983/Kaplan-Meier-curve-depicting-the-overall-survival-of-359-metastatic-papillary-renal-cell.png)
Kaplan-Meier curve depicting the overall survival of 359 metastatic... | Download Scientific Diagram
![Survival after complete surgical resection of multiple metastases from renal cell carcinoma - Alt - 2011 - Cancer - Wiley Online Library Survival after complete surgical resection of multiple metastases from renal cell carcinoma - Alt - 2011 - Cancer - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/bf31c0cc-87e7-4ff3-a158-bd339705b425/mfig001.jpg)
Survival after complete surgical resection of multiple metastases from renal cell carcinoma - Alt - 2011 - Cancer - Wiley Online Library
![Personalized Management of Advanced Kidney Cancer | American Society of Clinical Oncology Educational Book Personalized Management of Advanced Kidney Cancer | American Society of Clinical Oncology Educational Book](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/edbk/2018/edbk.2018.38/edbk_201215/20180622/images/large/edbk_201215_table1.jpeg)
Personalized Management of Advanced Kidney Cancer | American Society of Clinical Oncology Educational Book
![Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-018-0061-6/MediaObjects/41416_2018_61_Fig1_HTML.jpg)
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer
![Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-49250-6/MediaObjects/41598_2019_49250_Fig2_HTML.png)
Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients
![Overall survival curves for (A) all 140 patients with metastatic renal... | Download Scientific Diagram Overall survival curves for (A) all 140 patients with metastatic renal... | Download Scientific Diagram](https://www.researchgate.net/publication/263702696/figure/fig2/AS:667619061411855@1536184196912/Overall-survival-curves-for-A-all-140-patients-with-metastatic-renal-cell-carcinoma-and.png)
Overall survival curves for (A) all 140 patients with metastatic renal... | Download Scientific Diagram
![JCM | Free Full-Text | Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma JCM | Free Full-Text | Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma](https://pub.mdpi-res.com/jcm/jcm-09-01594/article_deploy/html/images/jcm-09-01594-g001.png?1590322290)
JCM | Free Full-Text | Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
![Overall survival of 180 patients with metastatic renal cell carcinoma... | Download Scientific Diagram Overall survival of 180 patients with metastatic renal cell carcinoma... | Download Scientific Diagram](https://www.researchgate.net/publication/301480827/figure/fig1/AS:485970496757760@1492875803905/Overall-survival-of-180-patients-with-metastatic-renal-cell-carcinoma-treated-with-IFN-a.png)
Overall survival of 180 patients with metastatic renal cell carcinoma... | Download Scientific Diagram
![Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study - European Urology Focus Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study - European Urology Focus](https://www.eu-focus.europeanurology.com/cms/attachment/7ef74f58-8f3a-40d2-aeb7-03e8669ff9ad/gr1_lrg.jpg)
Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study - European Urology Focus
![Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis](https://www.jcancer.org/v11/p7202/jcav11p7202g001.jpg)
Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis
![Cancers | Free Full-Text | Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors Cancers | Free Full-Text | Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors](https://pub.mdpi-res.com/cancers/cancers-12-00084/article_deploy/html/images/cancers-12-00084-g001.png?1581004963)